The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $93.35

Today's change+1.26 +1.37%
Updated September 2 4:00 PM EDT. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $93.35

Today's change+1.26 +1.37%
Updated September 2 4:00 PM EDT. Delayed by at least 15 minutes.

Johnson & Johnson up (U.S.)$1.26

Johnson & Johnson closed up Wednesday by (U.S.)$1.26 or 1.37% to (U.S.)$93.35. Over the last five days, shares have lost 1.85% and are down 10.73% for the last year to date. This security has underperformed the S&P 500 by 7.02% during the last year.

Key company metrics

  • Open(U.S.) $93.17
  • Previous close(U.S.) $92.09
  • High(U.S.) $93.47
  • Low(U.S.) $92.50
  • Bid / Ask(U.S.) $93.35 / (U.S.) $93.63
  • YTD % change-10.73%
  • Volume11,517,363
  • Average volume (10-day)14,090,696
  • Average volume (1-month)9,517,867
  • Average volume (3-month)8,099,470
  • 52-week range(U.S.) $81.79 to (U.S.) $109.49
  • Beta0.62
  • Trailing P/E16.44×
  • P/E 1 year forward14.93×
  • Forward PEG3.19×
  • Indicated annual dividend(U.S.) $3.00
  • Dividend yield3.21%
  • Trailing EPS(U.S.) $5.68
Updated September 2 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+22.41%

Based on its net profit margin of 22.41%, Johnson & Johnson is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 28, 201506/28/2015Mar 29, 201503/29/2015Dec 28, 201412/28/2014Sep 28, 201409/28/2014
Revenue17,78717,37418,25418,467
Total other revenue--------
Total revenue17,78717,37418,25418,467
Gross profit12,43012,09212,40113,068
Total cost of revenue5,3575,2825,8535,399
Total operating expense12,04611,79915,55111,657
Selling / general / administrative5,3844,8475,8225,468
Research & development2,1291,8992,6352,023
Depreciation / amortization--------
Interest expense (income), net operating131138139130
Unusual expense (income)001560
Other operating expenses, total-971-4321,016-1,347
Operating income5,7415,5752,7036,810
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax5,7415,5752,7036,810
Income after tax4,5164,3202,5214,749
Income tax, total1,2251,2551822,061
Net income4,5164,3202,5214,749
Total adjustments to net income--------
Net income before extra. items4,5164,3202,5214,749
Minority interest----0--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,5164,3202,5214,749
Inc. avail. to common incl. extra. items4,5164,3202,5214,749
Diluted net income4,5164,3202,5214,749
Dilution adjustment0--0--
Diluted weighted average shares2,8122,8262,8422,864
Diluted EPS excluding extraordinary itemsvalue per share1.611.530.891.66
Dividends per sharevalue per share0.750.700.700.70
Diluted normalized EPSvalue per share1.611.380.372.00